comparemela.com

Latest Breaking News On - Cancer medicine - Page 11 : comparemela.com

Dr Overman on Nonoperative Cancer Management in GI Malignancies

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.

United statesMichaelj overmanDivision of cancer medicineDepartment of gastrointestinal medical oncologyMd anderson cancer networkUniversity of texas md anderson cancer centerGastrointestinal medical oncologyCancer medicineExecutive committeeMedical staffCancer centerCancer networkThe university of texas md anderson cancer centerOnclive tvGastrointestinal cancer

CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC

The anti-CD70 CAR T-cell therapy CTX130 showed activity and manageable toxicities in advanced renal cell carcinoma.

United statesSan diegoSamera srourInternational metastatic renal cell carcinoma database consortiumDivision of cancer medicineUniversity of texas md anderson cancer centerDepartment of stem cell transplantationCancer discoveryStem cell transplantationCancer medicineCancer centerThe university of texas md anderson cancer centerGenitourinary cancer2023 aacr annual conferenceCobalt rcc

Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

United statesTimothya yapUniversity of texas md anderson cancer centerInvestigational cancer therapeuticsCancer medicineCancer centerBreast cancerHrr mutations

FDA Approval Insights: Ponatinib in Ph+ ALL

Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.

United statesElias jabbourCourtney flahertyUniversity of texas md anderson cancer centerDivision of cancer medicineDepartment of leukemiaLive on airCancer medicineCancer centerOnclive on airApple podcastsGoogle podcastsAmazon musicFda approval of ponatinibPatients with ph positive allPhallcon trial

Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

United statesKrinak patelDepartment of lymphoma myelomaUniversity of texas md anderson cancer centerDivision of cancer medicineCancer medicineCancer centerFda approval of ide celPatients with triple class exposed relapsed refractory multiple myeloma

vimarsana © 2020. All Rights Reserved.